BAVENCIO® (avelumab) is indicated for:
  • The maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy
  • The treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

BAVENCIO maintenance treatment is a STANDARD OF CARE for locally advanced or metastatic UC patients not progressing after platinum-containing chemotherapy1,2

National Comprehensive Cancer Network® (NCCN®) Recommendation

Avelumab maintenance is the ONLY NCCN CATEGORY 1 and PREFERRED immunotherapy option for both cisplatin-eligible and -ineligible patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed on first-line platinum-containing chemotherapy.3

Category 1=Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
NCCN=National Comprehensive Cancer Network® (NCCN®)
Preferred intervention=Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.